European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 546-551 , June 2010

A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study)

  • T. Yoshikawa

      Affiliations

    • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 45 391 5761; fax: +81 45 361 4692.
    • ,
  • K. Omura

      Affiliations

    • Department of Surgery, Kanazawa University, 13-1 Takara-machi, Kanazawa, Japan
    • ,
  • O. Kobayashi

      Affiliations

    • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan
    • ,
  • A. Nashimoto

      Affiliations

    • Department of Surgery, Niigata Cancer Center, 2-15-3 Kawagishi-cho, Chuo-Ku, Niigata 951-8566, Japan
    • ,
  • A. Takabayashi

      Affiliations

    • Department of Surgery, Kitano Hospital, 2-4-20 Ogicho, Kita-Ku, Osaka 530-8480, Japan
    • ,
  • T. Yamada

      Affiliations

    • Department of Surgery, Ishikawa Prefectural Central Hospital, 2-1 Kuratsukihigashi, Kanazawa 920-8530, Japan
    • ,
  • H. Yamaue

      Affiliations

    • Department of Surgery, Wakayama University, 811-1 Kimiidera, Wakayama 641-8510, Japan
    • ,
  • M. Fujii

      Affiliations

    • Department of Surgery, Nihon University, 1-8-13 Kandasurugadai, Chiyoda-Ku, Tokyo 101-8309, Japan
    • ,
  • T. Yamaguchi

      Affiliations

    • Department of Gastrointestinal Tract Surgery, Cancer Institute Hospital, 3-10-6 Ariake, Koto-Ku, Tokyo 135-8550, Japan
    • ,
  • T. Nakajima

      Affiliations

    • Japan Clinical Cancer Research Organization, 3-10-6 Ariake, Koto-Ku, Tokyo 135-8550, Japan

,Accepted 12 April 2010.

References 

  1. Torrado J, Santiseban A, Ruiz-Ederra J. Genetic susceptibility to gastric cancer. Hepato-Gastroenterology. 2001;48:1544–1547
  2. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274–275
  3. Maeta M, Yamashiro H, Saito H, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery. 1999;125:325–331
  4. Díaz de Liaño A, Yarnoz C, Aguilar R, et al. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96–102
  5. Nakajima T, Yamaguchi T. Gastric cancer database 1946–2004 in Cancer Institute Hospital. Tokyo: Kanehara & Co; 2006;
  6. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–2196
  7. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820
  8. Ott K, Lordick F, Hermann K, et al. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9
  9. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–2212
  10. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221
  11. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–4997
  12. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767–2773
  13. Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–1022
  14. Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer. 1998;1:10–24
  15. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–462
  16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  17. National Cancer Institute . Common Toxicity Criteria version 2.0 (CTC). 1999;Available from: http://ctep.cancer.gov/reporting/CTC-3.html
  18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  19. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20
  20. Baba H, Yamamoto M, Endo K, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–49
  21. Satoh S, Hasegawa S, Ozaki N, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using S-1/CDDP combination. Gastric Cancer. 2006;9:129–135
  22. Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer. 2007;10:29–34

PII: S0748-7983(10)00099-5

doi: 10.1016/j.ejso.2010.04.011

European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 546-551 , June 2010

Article Tools

* Image Usage & Resolution